Personalised Medicine in Colorectal Cancer?
description
Transcript of Personalised Medicine in Colorectal Cancer?
![Page 1: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/1.jpg)
Personalised Medicine in Colorectal Cancer?
Mr Arfon G M T Powell MB ChB MSc MRCSEdClinical Research Fellow in Surgery
![Page 2: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/2.jpg)
Colorectal cancer is the third most common cancer in the UK
39,991 new cases in 2008
Cancer Reseach UK. Bowel cancer statistics – UK, 2011. http://info.cancerresearchuk.org/cancerstats/types/bowel/
![Page 3: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/3.jpg)
• CRC is the 2nd most common cause of cancer-death• Accounting for 16,259 deaths in 2009
Cancer Mortality - UK statistics 2009
Lungs 22%
Bowel 10%
Breast 8%
Prostate 7%
Others 53%
Cancer Reseach UK. Cancer Mortality – UK Statistics 2011. http://info.cancerresearchuk.org/cancerstats/mortality/
![Page 4: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/4.jpg)
Treatment
• Treatment regimens are currently based on disease stage
• Surgery• Chemotherapy– Curative– Palliative
• Biological therapy
![Page 5: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/5.jpg)
![Page 6: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/6.jpg)
Prognosis
• Prognosis still remains stage dependent– Dukes’ A 93%– Dukes’ B 77%– Dukes’ C 48%
Cancer Reseach UK. Bowel cancer statistics – UK, 2011. http://www.cancerresearchuk.org/cancer-help/type/bowel-cancer/treatment/statistics-and-outlook-for-bowel-cancer#outlook
![Page 7: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/7.jpg)
http://www.hopkinscoloncancercenter.org/CMS/CMS_Page.aspx?CurrentUDV=59&CMS_Page_ID=1F7C07D4-268D-4635-8975-70A594870CC8
Surgical approach to colorectal cancer
![Page 8: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/8.jpg)
![Page 9: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/9.jpg)
![Page 10: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/10.jpg)
![Page 11: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/11.jpg)
![Page 12: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/12.jpg)
![Page 13: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/13.jpg)
![Page 14: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/14.jpg)
Variation in biomarker prognostic value
![Page 15: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/15.jpg)
Colorectal cancer development
• Accumulation of genetic alterations – Vogelstein
![Page 16: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/16.jpg)
Microsatellite Instability Phenotype
• Distinct genomic instability pathway • Microsatellite repeats • Associated with loss of mismatch repair
protein (MMR) function• Improved outcome
![Page 17: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/17.jpg)
![Page 18: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/18.jpg)
![Page 19: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/19.jpg)
Söreide K, Janssen EA, Söiland H, Körner H, Baak JP. Microsatellite instability in colorectal cancer. Br J Surg 2006; 93:395-406.
![Page 20: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/20.jpg)
![Page 21: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/21.jpg)
CpG Island Methylator Phenotype
Hypermethylation of cytosine- and guanine-rich stretches of DNA, called CpG islands, in the promoter region of genes causes transcriptional silencing and has been implicated in carcinogenesis
![Page 22: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/22.jpg)
![Page 23: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/23.jpg)
![Page 24: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/24.jpg)
![Page 25: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/25.jpg)
MSI/CIMP+
MSI/CIMP-Microsatellite stability status
CIMP status
CIMP status
CIMP +ve
CIMP -veMSI
MSS
MSS/CIMP+
MSS/CIMP-
CIMP +ve
CIMP -ve
![Page 26: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/26.jpg)
MSI/CIMP+
MSI/CIMP-Microsatellite stability status
CIMP status
CIMP status
CIMP +ve
CIMP -veMSI
MSS
MSS/CIMP+
MSS/CIMP-
CIMP +ve
CIMP -ve
Good survival
Poor survival
![Page 27: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/27.jpg)
MSI/CIMP+
MSI/CIMP-Microsatellite stability status
CIMP status
CIMP status
CIMP +ve
CIMP -veMSI
MSS
MSS/CIMP+
MSS/CIMP-
CIMP +ve
CIMP -ve
Prognostic information remains unclear
![Page 28: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/28.jpg)
![Page 29: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/29.jpg)
Serrated Adenocarcinoma
• Proximal location• MSI positive• Outcome variable which depends on tumour
site
http://kathrin.unibas.ch/polyp/bilder/gross/p015-03.jpg
Serrated AdenocarcinomaNon Serrated Adenocarcinoma
![Page 30: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/30.jpg)
Our experience with performing MSI and CIMP status analysis on
colorectal tumours
![Page 31: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/31.jpg)
Study design
• Retrospective study of 750 FFPE tumours• IHC for MMR proteins (MLH1, MSH2, MSH6 and PMS2)• 40% tumour required within the section for PCR• MSI PCR analysis of:– BAT 25– BAT 26– MONO 27– NR-21– NR-24
![Page 32: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/32.jpg)
Technical issues
• 55% of patients required macroscopic dissection to the equivalent of 2 10micron sections
![Page 33: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/33.jpg)
Technical issues
• 55% of patients required macroscopic dissection to the equivalent of 2 10micron sections
![Page 34: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/34.jpg)
MSI +ve
MSI -ve
![Page 35: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/35.jpg)
Preliminary results on 233 patients• Not significantly associated with:
– Increasing age (P=0.168)– Dukes stage (P=0.054)– Poor differentiation (P=0.362)– Vascular invasion (P=0.176)– Anaemia (P=0.192)– Raised CRP (P=0.374)– Hypoalbuminaemia (P=0.541)– Emergency presentation (P=0.943)
• Significantly associated with:– Right colon location (P<0.001)– Polypoid morphology (P=0.031)– Lower lymph node ratio (P=0.040)– Mucin production (P=0.009)– Serrated adenocarcinoma (P<0.001)
![Page 36: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/36.jpg)
P=0.042
The relationship between MSI status and cancer-specific survival
![Page 37: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/37.jpg)
CIMP study design
• Extracted DNA requires bisulfite conversion
• Followed by a methylight PCR assay for– CACNA1G– IGF2– NEUROG1– RUNX3– SOCS1
![Page 38: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/38.jpg)
DNA recovery following bisulfite treatment
• DNA recovery following bisulfite treatment is variable and does not reach the projected > 75%
Patient Input (ng) nano drop (ng/ul) DNA recovered (ng) Percentage recovered (%)
1 350 3.9 78 22.3
2 350 4.3 86 24.6
3 350 2.8 56 16.0
4 350 28 560 160.0
5 350 2.5 50 14.3
6 350 3.4 68 19.4
7 350 3.7 74 21.1
8 350 3.4 68 19.4
9 200 0.3 6 3.0
10 300 84 1680 560.0
11 350 1.7 34 9.7
12 200 64 1280 640.0
13 350 3.7 74 21.1
14 300 2.8 56 18.7
15 300 1.5 30 10.0
16 300 4.8 96 32.0
![Page 39: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/39.jpg)
MSI and CIMP status as predictors of response to treatment
![Page 40: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/40.jpg)
TreatmentA
Curative resection surgery
B
C Resection surgery + adjuvant therapy (eg. Chemothearpy)
D Dependent on tumour characteristics
![Page 41: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/41.jpg)
Treatment of colorectal cancer
• Surgery remains the primary modality for cure• Chemotherapy for high risk patients– Lymph node involvement– Locally advanced tumours
• MDT decision• Difficulty identifying patients that benefit from
chemotherapy
![Page 42: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/42.jpg)
Adjuvant Chemotherapy
• 2 major regimens for CRC treatment:– FOLFIRI (5-FU, folinic acid [Leucovorin], and
irinotecan [Campostar]) – FOLFOX (5-FU, folinic acid [Leucovorin], and
oxaliplatin [Eloxatin])
![Page 43: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/43.jpg)
Adjuvant Chemotherapy
• 2 major regimens for CRC treatment:– FOLFIRI (5-FU, folinic acid [Leucovorin], and
irinotecan [Campostar]) – FOLFOX (5-FU, folinic acid [Leucovorin], and
oxaliplatin [Eloxatin])• Results in context of MSI is conflicting
![Page 44: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/44.jpg)
![Page 45: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/45.jpg)
![Page 46: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/46.jpg)
Conclusions
• Colorectal cancer tumour heterogeneity exists• Techniques validated• MSI+/CIMP+ confers improved survival• Response to treatment remains unclear
![Page 47: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/47.jpg)
Acknowledgments
I would like to thank Dr David Baty and Christine Black (Molecular Genetics, Dundee) for their expertise with the MSI analysis
I would like to thank Rachael Ellis (Molecular Genetics, Glasgow) for her help with the bisulfite treatments
I would like to thank Clare Orange for her continued help over the last 3 years!
![Page 48: Personalised Medicine in Colorectal Cancer?](https://reader036.fdocuments.us/reader036/viewer/2022062316/5681671f550346895ddb9f61/html5/thumbnails/48.jpg)
Thank you!